Emergent BioSolutions (EBS) announced that its board of directors authorized the repurchase of up to $50M of the company’s common stock on or before March 31, 2027. “This new approval reflects the Board of Directors’ confidence in our ability to generate strong, sustainable cash flow and execute our capital allocation priorities for 2026 focused on growth, reducing debt and enabling long-term value creation for our shareholders,” said Joe Papa, president and CEO of Emergent. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50M of company’s common stock by March 27, 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Emergent BioSolutions gets FDA approval of sNDA for Narcan
- Former Emergent BioSolutions CEO sued by NY AG for insider trading
- Emergent BioSolutions outlines transformation and financial guidance at conference